Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.43 AUD | -1.15% | -6.52% | +24.64% |
May. 15 | Immutep Says Safety Lead-in Phase of Breast Cancer Study Yields 'Encouraging' Data | MT |
May. 15 | Immutep Limited Presents Data from Safety Lead-In Phase of AIPAC-003 at ESMO Breast 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+24.64% | 345M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.11% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- IMM Stock
- News Immutep Limited
- Immutep Validates Initial Efficacy of Immunotherapy Medication in Phase Two Cancer Trial